Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24034315 | 1.00 | PRKCA (0.39) | PRKCAELANE | |
| SCHEMBL1170858 | 0.80 | PRKCA (0.42) | PRKCAELANE | |
| SCHEMBL10417600 | 0.80 | PRKCA (0.42) | PRKCAELANE | |
| SCHEMBL6894109 | 0.75 | PRKCA (0.42) | PRKCAELANE | |
| SCHEMBL15702222 | 0.75 | PRKCA (0.42) | PRKCAELANE | |
| SCHEMBL6894202 | 0.75 | PRKCA (0.42) | PRKCAELANE | |
| Chloroform SCHEMBL8311136 | 0.74 | PRKCA (0.38) | PRKCAELANE | |
| SCHEMBL24792995 | 0.74 | — | — | |
| SCHEMBL3359533 | 0.74 | TSHR (0.35) | — | |
| SCHEMBL8211801 | 0.74 | PRKCA (0.45) | PRKCAELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712435-B2 | Mebendazole prodrugs with enhanced solubility and oral bioavailability | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-08-01 | — | — | US | disclosed |
| US-11712435-B2 | Mebendazole prodrugs with enhanced solubility and oral bioavailability | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-08-01 | — | — | US | disclosed |
| US-11712435-B2 | Mebendazole prodrugs with enhanced solubility and oral bioavailability | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-08-01 | — | — | US | disclosed |
| US-11618731-B2 | Prodrugs of kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| EP-3532057-B1 | PRODRUGS OF KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3532057-B1 | PRODRUGS OF KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220119407-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-04-21 | — | — | US | disclosed |
| US-11236109-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210205271-A1 | MEBENDAZOLE PRODRUGS WITH ENHANCED SOLUBILITY AND ORAL BIOAVAILABILITY | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. | 2021-07-08 | — | — | US | disclosed |
| US-20210205271-A1 | MEBENDAZOLE PRODRUGS WITH ENHANCED SOLUBILITY AND ORAL BIOAVAILABILITY | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. | 2021-07-08 | — | — | US | disclosed |
| US-20140275008-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275176-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275181-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| CN-1044243-C | Biphenyl-substituted quinoline derivatives | SQUIBB & SONS INC (US) | 1999-07-21 | — | — | CN | disclosed |
| US-5587374-A | BACTERICIDES TREATING INFECTIONS | GLAXO SPA (IT) | 1996-12-24 | — | — | US | disclosed |
| EP-0495953-B1 | 10-(1-Hydroxyethyl)-11-oxo-1-azatricyclo[7.2.0.0(3,8)]undec-2-ene-2-carboxylic acid esters and a process for preparing thereof | GLAXO SPA (IT) | 1994-06-08 | — | — | EP | disclosed |
| CN-1075720-A | The quinoline that xenyl replaces | SQUIBB & SONS INC (US) | 1993-09-01 | — | — | CN | disclosed |
| EP-0495953-A1 | 10-(1-Hydoxyethyl)-11-oxo-1-azatricyclo(7.2.0.0(3,8)undec-2-ene-2-carboxylic acid esters and a process for preparing thereof. | GLAXO SPA (IT) | 1992-07-29 | — | — | EP | disclosed |
| WO-1992003437-A1 | 10(1-HYDROXYETHYL)-11-OXO-1-AZATRICYCLO[7.2.0.0.3.8]UNDEC-2-ENE-2-CARBOXYLIC ACID ESTERS AND A PROCESS FOR PREPARING THEREOF | GLAXO S.P.A. (IT) | 1992-03-05 | — | — | WO | disclosed |
| US-4456465-A | HERBICIDES | ZOECON CORPORATION (US) | 1984-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275181-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | PRKCA 1592/4885ELANE 1881/4885 |
| US-11712435-B2 | Mebendazole prodrugs with enhanced solubility and oral bioavailability | CYP3A43, CYP3A4, CYP4B1 | PRKCA 4651/4885ELANE 517/4885 |
| US-20220119407-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | PRKCA 1592/4885ELANE 1881/4885 |
| US-20140275176-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | PRKCA 1592/4885ELANE 1881/4885 |
| US-11236109-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | PRKCA 1592/4885ELANE 1881/4885 |
| US-11618731-B2 | Prodrugs of kallikrein inhibitors | KLKB1, SERPINB1, KLK1 | PRKCA 1154/4885ELANE 36/4885 |
| US-20210205271-A1 | MEBENDAZOLE PRODRUGS WITH ENHANCED SOLUBILITY AND ORAL BIOAVAILABILITY | CYP3A43, CYP3A4, CYP4B1 | PRKCA 4651/4885ELANE 517/4885 |
| US-20140275008-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | PRKCA 1592/4885ELANE 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.